Weave Bio Raises $10M in Funding

Weave Bio, a New Haven, CT-based provider of a AI-native life sciences platform, raised $10M in funding.

The round was led by Innovation Endeavors and Magnetic Ventures.

The company intends to use the funds to accelerate its pursuit of streamlining the therapeutic lifecycle.

Led by CEO Ari Caroline, Weave Bio is an AI-native, life sciences company that provides an AI-enabled Regulatory Automation and Lifecycle Management (ReALM) platform for the pharma and biotech industries. With its flagship offering, AutoIND, it enables drug development teams to streamline the Investigational New Drug (IND) application process based on users’ own source data, regulatory guidelines, and public information, and build a living record of their therapeutic candidates.

FinSMEs

30/05/2024